Phoenix Toxicology & Lab Services

Phoenix Toxicology & Lab Services was paid $7.85M by Medicaid between Jan 2018 and Nov 2024, across 55 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 44% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Arizona

Rank by total paid#9 of 67

Median peer was paid$89K

This provider vs. median88×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	8,071	$66K
2019	1,169	$29K
2020	1,400	$17K
2021	4,830	$54K
2022	28,548	$2.19M
2023	59,335	$4.39M
2024incomplete	17,119	$1.11M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	44%	30,067	21,319	$3.47M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	22%	19,927	15,926	$1.76M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	19%	9,427	5,076	$1.46M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	9.0%	27,691	24,845	$707K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	3.5%	4,060	3,297	$278K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	1,263	930	$51K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	1,679	1,357	$25K
80050	General health panel	<1%	764	732	$15K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	1,074	1,027	$8K
84403		<1%	216	212	$6K
84402		<1%	215	211	$5K
82627		<1%	207	206	$5K

43 more codes

84270		<1%	214	$5K
84481		<1%	723	$4K
82607		<1%	1,025	$4K
83002		<1%	207	$4K
84443	Thyroid stimulating hormone (TSH)	<1%	684	$4K
80061	Lipid panel	<1%	1,022	$4K
82533		<1%	234	$3K
82746		<1%	855	$3K
82728		<1%	855	$3K
86141		<1%	641	$3K
80053	Comprehensive metabolic panel	<1%	921	$3K
83036	Hemoglobin; glycosylated (A1C)	<1%	1,127	$3K
84153		<1%	231	$3K
83525		<1%	207	$2K
84439		<1%	954	$2K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	726	$2K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	107	$2K
83735		<1%	1,027	$2K
83540		<1%	962	$1K
82150		<1%	644	$1K
84100		<1%	654	$1K
84550		<1%	670	$1K
82670		<1%	24	$676.72
86592		<1%	155	$540.45
84144		<1%	12	$250.32
83001		<1%	12	$222.96
83615		<1%	24	$153.00
84315		<1%	335	$105.00
80321		<1%	65	$100.56
83690		<1%	492	$81.06
84311		<1%	2,206	$37.50
83986		<1%	2,207	$21.50
82570		<1%	2,208	$15.00
80375		<1%	21	$3.66
84480		0%	221	$0.00
82550		0%	163	$0.00
86376		0%	190	$0.00
86140		0%	231	$0.00
86800		0%	13	$0.00
84436		0%	82	$0.00
36415	Collection of venous blood by venipuncture	0%	46	$0.00
84466		0%	472	$0.00
82947		0%	13	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMORTON, JONATHAN (MANAGING MEMBER)